Giovanni Longo

Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the GHOST registry

The Absorb bioresorbable vascular scaffold (Absorb BVS, Abbott Vascular, Santa Clara, California) promises to address some of the residual shortcomings of existing metallic stents, such as late events induced by permanent caging of the coronary vessel. Scaffold restenosis (ScR) of BVS has been poorly described so far and treatment strategies for this event remain to be codified. We report on a case series of 14 lesions in 12 patients presenting with ScR and discuss their anatomical features and management strategies.

Updates on NSAIDs in patients with and without coronary artery disease: pitfalls, interactions and cardiovascular outcomes

NSAIDs are used worldwide by more than 30 million people everyday, given their anti-inflammatory, analgesic and antipyretic effects. NSAIDs are approved for several common adult diseases, including acute and chronic musculoskeletal or inflammatory disease, osteoarthritis, rheumatoid arthritis and other arthritic conditions, as well as for children with juvenile idiopathic arthritis. Importantly, the population commonly taking NSAIDs is that of older individuals who also represent the population with the highest risk for cardiovascular (CV) and gastrointestinal adverse effects. In recent years, a growing body of evidence regarding potential risks from chronic use of NSAIDs has emerged. The aim of this review is to update the available data concerning chronic use of NSAIDs in patients with and without CV disease by analyzing the mechanisms of action, the interference of specific NSAIDs with the established CV protective role of low-dose aspirin, and the potential increased risk of myocardial infarction, stroke, hypertension, heart failure and atrial fibrillation.

New insights on acute expansion and longitudinal elongation of bioresorbable vascular scaffolds in vivo and at bench test: A note of caution on reliance to compliance charts and nominal length

We performed systematic optical coherence tomography (OCT) analyses after bioresorbable vascular scaffolds (BVS) implantation in a “real world” setting aiming at evaluating scaffold expansion and longitudinal integrity.

Longitudinal Elongation, Axial Compression, and Effects on Strut Geometry of Bioresorbable Vascular Scaffolds : Insights From 2- and 3-Dimensional Optical Coherence Tomography Imaging

Recently described, metallic drug-eluting stent longitudinal distortion is a mechanical phenomenon that leads to stent compression and strut separation (“pseudofracture”) during percutaneous coronary intervention [(1)][1]. Conversely, bioresorbable vascular scaffolds (BVS; Absorb, Abbott

Managing Bioabsorbable Vascular Scaffold Failure: Combined Scaffold Restenosis and Late-Acquired Coronary Aneurysm Treated With Self-Expandable Stent

A 50-year-old man underwent coronary angiography for stable angina with evidence of chronic total occlusion of the right coronary artery. Chronic total occlusion recanalization was performed with implantation of 4 overlapping bioresorbable vascular scaffolds. At 12 months, elective follow-up coronary angiography documented an asymptomatic 90% in-scaffold restenosis of the right coronary artery located in the mid portion of a newly late-acquired aneurysm. To address the challenging issue introduced by the varying reference vessel diameters, a self-expandable stent was implanted.

Tecnica di impianto dello scaffold coronarico riassorbibile Absorb TM nel registro IT-DISAPPEARS

Currently, one of the most relevant innovations in interventional cardiology is the advent of bioresorbable vascular scaffolds (BVS). Among the BVS developed so far, the AbsorbTM BVS 1.1 (Abbott®) is one of the two devices that achieved the CE mark for the use in clinical practice. A reasonable amount of clinical evidence on AbsorbTM BVS has been built up from a large series of trials, of which some have been completed and others are in the enrollment and/or follow-up phases. However, at present there is paucity of data on the efficacy and safety of AbsorbTM BVS in patients with more complex coronary artery disease, who represent the majority of those undergoing coronary stenting in everyday clinical practice. To fill this gap, several all-comers registries are ongoing, with the aim to assess the efficacy and safety of the scaffold in subgroups with particularly complex coronary lesions. The AbsorbTM BVS 1.1 registries include IT-DISAPPEARS (NCT02004730), an Italian multicenter registry, started in December 2013, and endorsed by the Italian Society of Invasive Cardiology (GISE). This registry will enroll only patients with long lesions and/or multivessel coronary disease, with an expected considerable proportion of included patients having complex disease. Therefore, the implementation of meticulous and appropriate implantation technique is of key importance for the accurate assessment of scaffold performance in a broad spectrum of coronary lesions. With the aim of standardizing the procedure for patients included in the IT-DISAPPEARS registry, the present article reports the technical features of Absorb TM BVS 1.1 implantation.

TCT-418 Procedural and mid-term outcomes of Bioresorbable scaffOlds versus drug-elutiNg stents In chronic Total Occlusions: the BONITO Registry

There is little evidence regarding the efficacy and safety of bioresorbable scaffolds (BRS) for the percutaneous treatment ofchronic total occlusions (CTO). The aim of this study was to investigate the clinical outcomes of patients with a CTO treated with BRS or drug-eluting stents (DES). We

Update on clinical evidence (Part II): A summary of the main post market studies: Update on BVS Clinical Evidence (Part II)

Bioresorbable vascular scaffolds (BVS, Absorb, Abbott Vascular, Santa Clara, CA) received the CE mark in October 2011, and were approved by the Food and Drug Administration in July 2016. After their introduction in clinical practice a broad amount of post‐marketing clinical experience with BVS has been generated so far in Europe and outside the United States. The available BVS registries differ in many aspects, including their being single‐center or multicenter, single‐arm or controlled, sponsored or investigator‐initiated, published or presented at a large‐scale international meeting. This article provides an overview of clinical results of the main post‐marketing studies of BVS available.